COMMUNIQUÉS West-GlobeNewswire
-
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
25/06/2026 -
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
25/06/2026 -
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
25/06/2026 -
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
25/06/2026 -
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
25/06/2026 -
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
25/06/2026 -
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
25/06/2026 -
Medera Announces Independent Data Monitoring Committee (DMC) Recommends Continued Advancement of Lead HFpEF Gene Therapy Program
25/06/2026 -
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
25/06/2026 -
The LaVie Institute Introduces Less-Invasive Breast Augmentation Technique with Rapid Recovery
25/06/2026 -
Data Presented on Two-Year Proximal Neck Dynamics from First-in-Human Study of Abdominal Aortic Aneurysm Treatment
25/06/2026 -
NIMA and RA Capital Launch First-of-Its-Kind Workplace Pilot to Support Employees with Celiac Disease
25/06/2026 -
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
25/06/2026 -
New PerfectServe Research: 85% of Healthcare Leaders Want to Switch Their Contact Center Vendors, But Most Feel Trapped
25/06/2026 -
Atalan Launches Nurse Retention Platform Designed to Identify Risk Up to 12 Months in Advance
25/06/2026 -
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
25/06/2026 -
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
25/06/2026 -
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
25/06/2026 -
TRUE-See Selected to Participate in Microsoft for Start-Ups Azure AI Program to Accelerate Innovation and Growth
25/06/2026
Pages